BridgeBio Oncology Therapeutics, Inc 10-Q for FY2026 Q3
BridgeBio Oncology Therapeutics, Inc. (BBOT)
10-Q
2026-11-10
For: 2026-09-30
View Original
Added on
November 10, 2026
About this 10-Q
BridgeBio Oncology Therapeutics, Inc filed this 10-Q on November 10, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).
BBOT reported a nine-month net loss of $132.7 million as research and development expenses increased to $118.6 million. Cash, cash equivalents and marketable securities totaled $315.3 million as of September 30, 2026. AI summary
Headline figures
Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.
- Net loss
- $34.18M
- compared with a net loss of $44.76M a year earlier
- Diluted EPS
- -$0.43
- compared with -$1.03 a year earlier